开云app官网登录入口网页版-官方正版

#三期临床#

55篇内容 | 1672人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1991344, encodeId=c3e319913444e, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）, objectType=article, longId=723632, objectId=b0e5e23632a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e5e23632a1, replyNumber=0, likeNumber=75, createdTime=2022-08-20, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e5e23632a1, moduleTitle=开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b0e5e23632a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991346, encodeId=7905199134689, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=JAMA：二甲双胍面对乳腺癌，没了“神通”！三期临床研究显示，非糖尿病早期乳腺癌患者服用二甲双胍进行辅助治疗，无法改善生存, objectType=article, longId=728397, objectId=e43be283979e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e43be283979e, replyNumber=0, likeNumber=0, createdTime=2023-04-15, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e43be283979e, moduleTitle=JAMA：二甲双胍面对乳腺癌，没了“神通”！三期临床研究显示，非糖尿病早期乳腺癌患者服用二甲双胍进行辅助治疗，无法改善生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e43be283979e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991343, encodeId=47eb199134349, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, objectType=article, longId=300977, objectId=fd013009e7ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd013009e7ec, replyNumber=0, likeNumber=73, createdTime=2022-11-26, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd013009e7ec, moduleTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd013009e7ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991345, encodeId=7b921991345ee, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, objectType=article, longId=727732, objectId=4596e27732ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4596e27732ba, replyNumber=0, likeNumber=79, createdTime=2023-03-04, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4596e27732ba, moduleTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4596e27732ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991342, encodeId=ba52199134274, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, objectType=article, longId=292989, objectId=e862292989a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e862292989a0, replyNumber=0, likeNumber=103, createdTime=2022-10-13, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e862292989a0, moduleTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e862292989a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991341, encodeId=7c9a199134116, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种, objectType=article, longId=217197, objectId=d53a21e197bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d53a21e197bf, replyNumber=0, likeNumber=85, createdTime=2022-01-09, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d53a21e197bf, moduleTitle=欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d53a21e197bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991336, encodeId=76701991336a9, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, objectType=article, longId=208253, objectId=ad502082536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad502082536a, replyNumber=0, likeNumber=65, createdTime=2021-09-09, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad502082536a, moduleTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad502082536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991335, encodeId=4fc91991335d8, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, objectType=article, longId=207609, objectId=8af020e60938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8af020e60938, replyNumber=0, likeNumber=106, createdTime=2021-02-28, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8af020e60938, moduleTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8af020e60938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991339, encodeId=94261991339f2, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Nat Med：摇头丸治疗创伤后应激障碍PTSD的三期临床实验结果发布, objectType=article, longId=211418, objectId=b662211418c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b662211418c8, replyNumber=0, likeNumber=110, createdTime=2021-12-12, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b662211418c8, moduleTitle=Nat Med：摇头丸治疗创伤后应激障碍PTSD的三期临床实验结果发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b662211418c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991337, encodeId=c02c199133e53, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=阿斯利康新冠疫苗美国三期临床有效率达79%，血栓或可被治愈, objectType=article, longId=208896, objectId=1a162088965d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a162088965d, replyNumber=0, likeNumber=72, createdTime=2022-01-14, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a162088965d, moduleTitle=阿斯利康新冠疫苗美国三期临床有效率达79%，血栓或可被治愈, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1a162088965d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991332, encodeId=f0111991332db, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！, objectType=article, longId=201127, objectId=84cb20112e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84cb20112e76, replyNumber=0, likeNumber=111, createdTime=2021-05-23, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84cb20112e76, moduleTitle=Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=84cb20112e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991329, encodeId=a05019913294c, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验, objectType=article, longId=200492, objectId=53c7200492b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53c7200492b6, replyNumber=0, likeNumber=84, createdTime=2020-09-28, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53c7200492b6, moduleTitle=因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=53c7200492b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991334, encodeId=8d4d199133467, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%, objectType=article, longId=203490, objectId=f3d72034907f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d72034907f, replyNumber=0, likeNumber=116, createdTime=2021-09-09, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d72034907f, moduleTitle=又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f3d72034907f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991331, encodeId=4b691991331b8, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, objectType=article, longId=200679, objectId=181a2006e961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=181a2006e961, replyNumber=0, likeNumber=101, createdTime=2021-02-24, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=181a2006e961, moduleTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=181a2006e961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991340, encodeId=abab199134011, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, objectType=article, longId=212858, objectId=6bb6212858c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb6212858c0, replyNumber=0, likeNumber=78, createdTime=2022-05-10, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb6212858c0, moduleTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6bb6212858c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991326, encodeId=cd781991326e7, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=张文宏谈部分国家疫苗“紧急接种”：不用焦虑拭目以待三期临床结果, objectType=article, longId=199341, objectId=7d4919934123, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d4919934123, replyNumber=0, likeNumber=127, createdTime=2020-09-19, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d4919934123, moduleTitle=张文宏谈部分国家疫苗“紧急接种”：不用焦虑拭目以待三期临床结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7d4919934123)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991338, encodeId=53ab199133845, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=科兴灭活疫苗巴西三期临床试验结果出炉！, objectType=article, longId=209930, objectId=412420993098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=412420993098, replyNumber=0, likeNumber=81, createdTime=2021-08-24, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=412420993098, moduleTitle=科兴灭活疫苗巴西三期临床试验结果出炉！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=412420993098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991333, encodeId=e4b41991333f4, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=孤儿药avatrombopag用于化疗诱导的血小板减少症三期临床失败, objectType=article, longId=202056, objectId=81e420205666, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e420205666, replyNumber=0, likeNumber=113, createdTime=2021-08-24, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e420205666, moduleTitle=孤儿药avatrombopag用于化疗诱导的血小板减少症三期临床失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=81e420205666)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991330, encodeId=8e80199133094, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=阿斯利康/牛津新冠疫苗三期临床将重启, objectType=article, longId=200623, objectId=72d920062336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d920062336, replyNumber=0, likeNumber=114, createdTime=2021-05-09, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d920062336, moduleTitle=阿斯利康/牛津新冠疫苗三期临床将重启, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=72d920062336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991328, encodeId=36061991328d9, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制, objectType=article, longId=200464, objectId=cb582004641e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb582004641e, replyNumber=0, likeNumber=86, createdTime=2021-05-13, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb582004641e, moduleTitle=阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb582004641e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

三期临床

2020-05-29

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）

2022-08-20

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

JAMA：二甲双胍面对乳腺癌，没了“神通”！三期临床研究显示，非糖尿病早期乳腺癌患者服用二甲双胍进行辅助治疗，无法改善生存

2023-04-15

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

我国自主研发的抗新冠口服药 VV116 启动三期临床研究

2022-11-26

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功

2023-03-04

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？

2022-10-13

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种

2022-01-09

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展

2021-09-09

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格

2021-02-28

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Nat Med：摇头丸治疗创伤后应激障碍PTSD的三期临床实验结果发布

2021-12-12

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

阿斯利康新冠疫苗美国三期临床有效率达79%，血栓或可被治愈

2022-01-14

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！

2021-05-23

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验

2020-09-28

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%

2021-09-09

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓

2021-02-24

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加

2022-05-10

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

张文宏谈部分国家疫苗“紧急接种”：不用焦虑拭目以待三期临床结果

2020-09-19

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

科兴灭活疫苗巴西三期临床试验结果出炉！

2021-08-24

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

孤儿药avatrombopag用于化疗诱导的血小板减少症三期临床失败

2021-08-24

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

阿斯利康/牛津新冠疫苗三期临床将重启

2021-05-09

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制

2021-05-13

科室
- - 订阅+
  - 更多科室
工具
服务